The present invention provides novel and improved stimulus responsive polymers and methods of using the same for the purification of biomolecules.

The present invention provides a method for concentrating a protein, in particular a method for concentrating a plasma product, in particular IgG, using glycine in a two-stage ultrafiltration/diafiltration approach.

The present invention provides a method for concentrating a protein, in particular a method for concentrating a plasma product, in particular IgG, using glycine in a two-stage ultrafiltration/diafiltration approach.

The present disclosure provides fluidic devices and fluidic device assemblies, including microfluidic devices and cartridges comprising the same, that in illustrative embodiments, can be used to make particles or protein precipitates, or to monitor precipitate formation. The fluidic devices typically include channels that connect a reaction well to an inlet port and an outlet port, and a fluidic constriction channel that is configured to help retain fluids in the reaction well and/or promote mixing within the reaction well. In some aspect, fluidic devices are interconnected into fluidic assemblies that can be used in continuous process methods.

The present disclosure provides fluidic devices and fluidic device assemblies, including microfluidic devices and cartridges comprising the same, that in illustrative embodiments, can be used to make particles or protein precipitates, or to monitor precipitate formation. The fluidic devices typically include channels that connect a reaction well to an inlet port and an outlet port, and a fluidic constriction channel that is configured to help retain fluids in the reaction well and/or promote mixing within the reaction well. In some aspect, fluidic devices are interconnected into fluidic assemblies that can be used in continuous process methods.

The present invention relates to a botulinum toxin preparation method capable of obtaining botulinum toxin in a high yield through a simplified process that does not include animal-derived ingredients. The botulinum toxin preparation method according to the present invention does not use any animal ingredients in the overall process, including the culturing of a Clostridium botulinum strain, thereby providing excellent safety, omits a separate nucleic acid removal step using an additive treatment when compared with a conventional isolation process, and performs processing using only ion exchange chromatography, and it was confirmed that the botulinum toxin can be isolated at a remarkably improved yield through a simplified process by using the same buffer and only adjusting the concentration and pH of the buffer, and thus the present invention is a very economical and efficient isolation method so that the botulinum toxin isolated thereby is expected to be effectively used in beauty and medicine fields.

The present invention relates to a botulinum toxin preparation method capable of obtaining botulinum toxin in a high yield through a simplified process that does not include animal-derived ingredients. The botulinum toxin preparation method according to the present invention does not use any animal ingredients in the overall process, including the culturing of a Clostridium botulinum strain, thereby providing excellent safety, omits a separate nucleic acid removal step using an additive treatment when compared with a conventional isolation process, and performs processing using only ion exchange chromatography, and it was confirmed that the botulinum toxin can be isolated at a remarkably improved yield through a simplified process by using the same buffer and only adjusting the concentration and pH of the buffer, and thus the present invention is a very economical and efficient isolation method so that the botulinum toxin isolated thereby is expected to be effectively used in beauty and medicine fields.

The present invention relates to a method for preparing a concentrate of polyvalent immunoglobulins with view to therapeutic use, from an initial solution of blood plasma or a plasma fraction enriched with immunoglobulins, comprising the steps for removing the protein contaminants by precipitation with caprylic acid in order to obtain a solution free of proteases, and for separating by chromatography on a fluidized bed the solution free of proteases, said method allowing a concentrate of human polyvalent immunoglobulins with a yield of more than 4.5 g of immunoglobulins per liter of blood plasma applied to be obtained.

The present invention relates to a method for preparing a concentrate of polyvalent immunoglobulins with view to therapeutic use, from an initial solution of blood plasma or a plasma fraction enriched with immunoglobulins, comprising the steps for removing the protein contaminants by precipitation with caprylic acid in order to obtain a solution free of proteases, and for separating by chromatography on a fluidized bed the solution free of proteases, said method allowing a concentrate of human polyvalent immunoglobulins with a yield of more than 4.5 g of immunoglobulins per liter of blood plasma applied to be obtained.

Precipitation promoters, which are an organic compound having one or more linear aliphatic hydrocarbon groups having not less than 10 carbon atoms, wherein the aliphatic hydrocarbon group has not less than 20 carbon atoms in total are useful for precipitating an organic compound protected by an organic group having one or more aliphatic hydrocarbon groups having not less than 10 carbon atoms from a solvent.